Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Managing Suboptimal CD4+ Cell Count Increase Despite Suppressive ART

Listen as William R. Short, MD, MPH, AAHIVS, discusses the data supporting guideline recommendations about the consequences of suboptimal CD4+ cell count, whether to intensify therapy, switch ART, and more.
William R. Short, MD, MPH, AAHIVS
Released: November 19, 2021

In this episode, William R. Short, MD, MPH, AAHIVS, explores recommendations and data on strategies to address suboptimal CD4+ cell count response in people with HIV on suppressive ART.

Listen as he gives his perspectives on:

  • The consequences of suboptimal CD4+ cell count response
  • ART intensification
  • ART switch strategies with data from the SPIRAL study
  • Data on the addition of interleukin-2 from the SILCAAT and ESPIRIT studies
  • DHHS guideline recommendations

Information on this Educational Activity

Faculty

William R. Short, MD, MPH, AAHIVS

Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

William R. Short, MD, MPH, AAHIVS, has disclosed that he has received fees for non-CME/CE services from Janssen and consulting fees from ViiV.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

One patient’s journey from HIV diagnosis to undetectable while trying to lose weight, from Clinical Care Options (CCO)

person default Anonymous Patient Released: November 29, 2021

Perspective on ART modification to reduce CVD risk in PWH, from Dr Jens D. Lundgren and Clinical Care Options (CCO)

Jens D. Lundgren, MD, DMSc Released: November 29, 2021

Slides from CCO: Discussion of key data and recommendations for choosing ART regimens for patients with virologic failure and resistance

W. David Hardy, MD Josep M. Llibre, MD, PhD Released: November 29, 2021

Dr Milena Murray and Clinical Care Options (CCO): Data suggests patient factors that may inform candidacy for LA CAB + RPV as a treatment option

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Released: November 24, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue